Long-range financial modeling and algorithmic stock forecast platforms project that McKesson Corporation (MCK) shares could experience significant appreciation by 2030, with consensus estimates suggesting average target valuations ranging upward toward $1,150 to over $2,000 per share depending on the prediction methodology. These optimistic forecasts are anchored by expectations of steady healthcare demand, robust pharmaceutical distribution volume expansion, and disciplined corporate buyback programs, though long-term projections carry inherent market volatility.